We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OptimizeRx Corporation (OPRX - Free Report) stock has lost 30.4% in the past month compared with the Zacks Computer Software industry’s decline of 0.8%. The stock has also underperformed the Zacks Computer & Technology sector and the S&P 500 composite growth of 9.2% and 4.9%, respectively.
The stock has underperformed its peers, such as Omnicell (OMCL - Free Report) , Doximity (DOCS - Free Report) , and Veeva Systems (VEEV - Free Report) . OMCL has gained 19.2% while DOCS and VEEV lost 20.2% and 2.7%, respectively, in the same time frame.
Image Source: Zacks Investment Research
Investors may wonder whether OPRX has further downside risk or if its underlying fundamentals can help stabilize the stock. Let’s examine the company’s strengths, operational challenges and growth outlook to determine the best course of action.
Key Factors to Consider
OptimizeRx’s near-term performance remains under pressure due to ongoing macroeconomic challenges and disruption related to most favored nation (MFN) pricing dynamics, which have resulted in more cautious customer spending, shorter contract durations and delayed campaign timing. On the last earnings call, management highlighted that visibility into the full year remains limited, prompting the company to lower its 2026 revenue guidance to $95-$100 million from prior expectations. Revenue in the first quarter declined 10% year over year to $19.8 million, reflecting softness in the contracted revenue base and weaker spending patterns among certain pharmaceutical customers.
The company also continues to face customer-specific execution challenges that negatively impact growth and guidance visibility. Management highlighted that one major client remains disrupted due to a combination of MFN-related pressures, internal customer changes and execution shortcomings on OptimizeRx’s side. Contracted revenue declined 15-20% year over year because clients are increasingly opting for shorter-duration agreements instead of the typical six-to-12-month commitments, limiting backlog visibility and increasing renewal risk throughout the year.
Cash flow and balance sheet metrics also reflected some pressure during the first quarter. Cash and cash equivalents declined to $20.2 million at the end of the first quarter from $23.4 million at the end of 2025, while operating cash flow turned negative, primarily due to bonus payouts and sales commission payments. Although debt levels improved following repayments, the company still carried $23.6 million in debt exiting the quarter. In addition, average revenue per top 20 pharmaceutical manufacturers declined year over year, while net revenue retention softened slightly to 110% from 114%, indicating moderating expansion within existing accounts.
OptimizeRx Corp. Price, Consensus and EPS Surprise
Despite these headwinds, OptimizeRx delivered improved profitability metrics in the first quarter, supported by cost optimization efforts and a favorable product mix. Adjusted EBITDA more than doubled year over year to $3.3 million, while non-GAAP net income increased to $2.7 million from $1.5 million in the prior-year period. The company also maintained its adjusted EBITDA guidance of $21-$25 million despite lowering revenue expectations, reflecting confidence in operating leverage, efficiency initiatives and margin improvement strategies. Management expects annualized savings of approximately $3 million from recently launched operating efficiency programs.
The company is also benefiting from strong momentum in its AI-enabled DAAP platform and subscription-based offerings. DAAP revenue grew 60% in the first quarter, while DAAP subscription revenue increased 45%, highlighting growing customer adoption and improving revenue durability. Management also noted increasing traction among mid-tier and long-tail life sciences customers, alongside expanding opportunities in medtech, where pilot programs are evolving into multimillion-dollar engagements.
OptimizeRx is further strengthening its long-term outlook through strategic platform expansion and improved financial flexibility. The company recently enabled demand-side platforms controlling more than 80% of digital promotional spending to connect directly into its proprietary EHR network, opening a potentially significant new revenue channel. Management believes this initiative could materially increase inventory utilization and drive substantial long-term growth beginning in late 2026 and accelerating into 2027. Additionally, the refinancing of its debt with Fifth Third Bank reduced borrowing costs by approximately 625 basis points, which is expected to generate around $1.5 million in annual interest expense savings and improve overall financial flexibility.
OPRX’s Estimate Revision Trend Unfavorable
OPRX’s estimates are currently on a downward trajectory. The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2027 has been revised downward over the past 60 days.
Image Source: Zacks Investment Research
A Look at OPRX’s Valuation
OPRX is trading at a forward 12-month price/sales ratio of 0.88, lower than the sector’s multiple of 6.71.
Image Source: Zacks Investment Research
OMCL, DOCS and VEEV are trading at a forward 12-month price/sales ratio of 1.58, 5.16 and 7.19, respectively.
Should You Hold or Sell Now?
Given OPRX’s weakening revenue visibility, ongoing customer-related disruptions and downward estimate revisions, investors should stay on the sidelines until the company demonstrates a more stable growth trajectory and improved business momentum.
View the Zacks #1 Rank List
Image: Bigstock
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
Key Takeaways
OptimizeRx Corporation (OPRX - Free Report) stock has lost 30.4% in the past month compared with the Zacks Computer Software industry’s decline of 0.8%. The stock has also underperformed the Zacks Computer & Technology sector and the S&P 500 composite growth of 9.2% and 4.9%, respectively.
The stock has underperformed its peers, such as Omnicell (OMCL - Free Report) , Doximity (DOCS - Free Report) , and Veeva Systems (VEEV - Free Report) . OMCL has gained 19.2% while DOCS and VEEV lost 20.2% and 2.7%, respectively, in the same time frame.
Image Source: Zacks Investment Research
Investors may wonder whether OPRX has further downside risk or if its underlying fundamentals can help stabilize the stock. Let’s examine the company’s strengths, operational challenges and growth outlook to determine the best course of action.
Key Factors to Consider
OptimizeRx’s near-term performance remains under pressure due to ongoing macroeconomic challenges and disruption related to most favored nation (MFN) pricing dynamics, which have resulted in more cautious customer spending, shorter contract durations and delayed campaign timing. On the last earnings call, management highlighted that visibility into the full year remains limited, prompting the company to lower its 2026 revenue guidance to $95-$100 million from prior expectations. Revenue in the first quarter declined 10% year over year to $19.8 million, reflecting softness in the contracted revenue base and weaker spending patterns among certain pharmaceutical customers.
The company also continues to face customer-specific execution challenges that negatively impact growth and guidance visibility. Management highlighted that one major client remains disrupted due to a combination of MFN-related pressures, internal customer changes and execution shortcomings on OptimizeRx’s side. Contracted revenue declined 15-20% year over year because clients are increasingly opting for shorter-duration agreements instead of the typical six-to-12-month commitments, limiting backlog visibility and increasing renewal risk throughout the year.
Cash flow and balance sheet metrics also reflected some pressure during the first quarter. Cash and cash equivalents declined to $20.2 million at the end of the first quarter from $23.4 million at the end of 2025, while operating cash flow turned negative, primarily due to bonus payouts and sales commission payments. Although debt levels improved following repayments, the company still carried $23.6 million in debt exiting the quarter. In addition, average revenue per top 20 pharmaceutical manufacturers declined year over year, while net revenue retention softened slightly to 110% from 114%, indicating moderating expansion within existing accounts.
OptimizeRx Corp. Price, Consensus and EPS Surprise
OptimizeRx Corp. price-consensus-eps-surprise-chart | OptimizeRx Corp. Quote
Despite these headwinds, OptimizeRx delivered improved profitability metrics in the first quarter, supported by cost optimization efforts and a favorable product mix. Adjusted EBITDA more than doubled year over year to $3.3 million, while non-GAAP net income increased to $2.7 million from $1.5 million in the prior-year period. The company also maintained its adjusted EBITDA guidance of $21-$25 million despite lowering revenue expectations, reflecting confidence in operating leverage, efficiency initiatives and margin improvement strategies. Management expects annualized savings of approximately $3 million from recently launched operating efficiency programs.
The company is also benefiting from strong momentum in its AI-enabled DAAP platform and subscription-based offerings. DAAP revenue grew 60% in the first quarter, while DAAP subscription revenue increased 45%, highlighting growing customer adoption and improving revenue durability. Management also noted increasing traction among mid-tier and long-tail life sciences customers, alongside expanding opportunities in medtech, where pilot programs are evolving into multimillion-dollar engagements.
OptimizeRx is further strengthening its long-term outlook through strategic platform expansion and improved financial flexibility. The company recently enabled demand-side platforms controlling more than 80% of digital promotional spending to connect directly into its proprietary EHR network, opening a potentially significant new revenue channel. Management believes this initiative could materially increase inventory utilization and drive substantial long-term growth beginning in late 2026 and accelerating into 2027. Additionally, the refinancing of its debt with Fifth Third Bank reduced borrowing costs by approximately 625 basis points, which is expected to generate around $1.5 million in annual interest expense savings and improve overall financial flexibility.
OPRX’s Estimate Revision Trend Unfavorable
OPRX’s estimates are currently on a downward trajectory. The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2027 has been revised downward over the past 60 days.
Image Source: Zacks Investment Research
A Look at OPRX’s Valuation
OPRX is trading at a forward 12-month price/sales ratio of 0.88, lower than the sector’s multiple of 6.71.
Image Source: Zacks Investment Research
OMCL, DOCS and VEEV are trading at a forward 12-month price/sales ratio of 1.58, 5.16 and 7.19, respectively.
Should You Hold or Sell Now?
Given OPRX’s weakening revenue visibility, ongoing customer-related disruptions and downward estimate revisions, investors should stay on the sidelines until the company demonstrates a more stable growth trajectory and improved business momentum.
OPRX currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.